Literature DB >> 1653806

Differential inhibition of human neutrophil activation by cyclosporins A, D, and H. Cyclosporin H is a potent and effective inhibitor of formyl peptide-induced superoxide formation.

K Wenzel-Seifert1, L Grünbaum, R Seifert.   

Abstract

Cyclosporin (Cs)A but not CsH inhibits activation of human lymphocytes. We studied the effects of CsA, CsD, and CsH on human neutrophil activation induced by chemoattractants and by various substances that circumvent receptor stimulation. CsH inhibited superoxide (O2-) formation induced by the chemotactic peptide, FMLP (30 nM), with a half-maximal effect at 40 nM. O2- formation was abolished by CsH at 1 microM. CsH increased the concentration of FMLP causing half-maximal activation of O2- formation from 30 nM to 0.8 microM and substantially reduced the stimulatory effect of FMLP at supra-maximally effective concentrations. The inhibitory effect of CsH on O2- formation was evident immediately after addition to neutrophils. CsH also markedly inhibited the increase in cytosolic Ca2+ ([Ca2+]i), beta-glucuronidase, and lysozyme release and aggregation stimulated by FMLP. CsA and CsD were considerably less effective than CsH to inhibit FMLP-induced O2- formation. CsA and CsD were without effect on exocytosis, rises in [Ca2+]i, and aggregation induced by the chemotactic peptide. Cyclosporines inhibited FMLP-induced O2- formation in an additive manner, indicating that they acted through a mechanism they had in common. Cyclosporines only slightly inhibited O2- formation and lysozyme release induced by C5a. Aggregation and rises in [Ca2+]i stimulated by C5a were not affected by cyclosporines, and they did not inhibit O2- formation and exocytosis induced by platelet-activating factor and leukotriene B4. Cyclosporines partially inhibited O2- formations induced by NaF and gamma-hexachlorocyclohexane. CsA marginally inhibited PMA-induced O2- formation and lysozyme release. CsA, CsD, and CsH did not inhibit arachidonic acid-induced O2- formation and its potentiation by NaF or stable guanine nucleotides in a cell-free system from DMSO-differentiated HL-60 cells. CsH partially inhibited binding of FML [3H]P to formyl peptide receptors in membranes from DMSO- or dibutyryl cAMP-differentiated HL-60 cells. Our data show that: 1) cyclosporines differentially inhibit activation of human neutrophils; and 2) CsH is, indeed, not immunologically inactive but is a potent and effective inhibitor of FMLP-induced O2- formation. 3) CsH interferes with agonist binding to formyl peptide receptors and in addition, cyclosporines may also act at sites distal to chemoattractant receptors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1653806

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Effect of cyclosporin analogues on histamine release from rat peritoneal mast cells and rat basophilic leukaemia cells.

Authors:  B Y Wan; M N Ho; E S Assem
Journal:  Inflamm Res       Date:  1995-04       Impact factor: 4.575

2.  N-formyl-methionyl-leucyl-phenylalanine (fMLP) promotes osteoblast differentiation via the N-formyl peptide receptor 1-mediated signaling pathway in human mesenchymal stem cells from bone marrow.

Authors:  Min Kyoung Shin; Young Hoon Jang; Hyun Jung Yoo; Dong Woo Kang; Mi Hee Park; Mi Kyoung Kim; Ju Hyun Song; Sang Doo Kim; Gyesik Min; Hyung Keun You; Kang-Yell Choi; Yoe-Sik Bae; Do Sik Min
Journal:  J Biol Chem       Date:  2011-03-03       Impact factor: 5.157

3.  Thapsigargin activates univalent- and bivalent-cation entry in human neutrophils by a SK&F I3 96365- and Gd3+-sensitive pathway and is a partial secretagogue: involvement of pertussis-toxin-sensitive G-proteins and protein phosphatases 1/2A and 2B in the signal-transduction pathway.

Authors:  K Wenzel-Seifert; D Krautwurst; I Musgrave; R Seifert
Journal:  Biochem J       Date:  1996-03-01       Impact factor: 3.857

4.  Dihydroxyoctadecamonoenoate esters inhibit the neutrophil respiratory burst.

Authors:  David Alan Thompson; Bruce D Hammock
Journal:  J Biosci       Date:  2007-03       Impact factor: 1.826

5.  Comparison of the properties of the CsA analogs monoacetyl CyC (o-acetyl-threonine2 cyclosporin) and methyl-alanyl CsA (N-methyl-L-alanyl6 cyclosporin); monoacetyl cyclosporin is immunosuppressive without binding to cyclophilin.

Authors:  S el Rouby; Y Shi; G H Reem
Journal:  Clin Exp Immunol       Date:  1992-07       Impact factor: 4.330

Review 6.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

7.  Partial inhibition of human neutrophil activation by FK-506 at supratherapeutic concentrations.

Authors:  K Wenzel-Seifert; R Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-07       Impact factor: 3.000

8.  Etretinate or cyclosporin-A treatment normalizes the enhanced respiratory burst of polymorphonuclear leukocytes in psoriasis.

Authors:  R E Schopf; J Höcher; M Rehder; L Färber; B Morsches
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

9.  Antimicrobial peptide scolopendrasin VII, derived from the centipede Scolopendra subspinipes mutilans, stimulates macrophage chemotaxis via formyl peptide receptor 1.

Authors:  Yoo Jung Park; Ha Young Lee; Young Su Jung; Joon Seong Park; Jae Sam Hwang; Yoe-Sik Bae
Journal:  BMB Rep       Date:  2015-08       Impact factor: 4.778

10.  The immune-stimulating peptide WKYMVm has therapeutic effects against ulcerative colitis.

Authors:  Sang Doo Kim; Soonil Kwon; Sung Kyun Lee; Minsoo Kook; Ha Young Lee; Ki-Duk Song; Hak-Kyo Lee; Suk-Hwan Baek; Chan Bae Park; Yoe-Sik Bae
Journal:  Exp Mol Med       Date:  2013-09-13       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.